Last update Aug. 19, 2021

Auranofin

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Gold compound with anti-inflammatory properties. Other similar compounds are aurothiomalate and aurothioglucose.
Used as a disease-modifying antirheumatic drug (DMARD) in active rheumatoid arthritis and psoriatic arthritis.
Oral administration once or twice a day.

At the date of the last update, the authors did not find any published data on its excretion in breast milk.

Its pharmacokinetic data (low protein binding and very long half-life) make it probable that it will pass into breast milk in an amount that could be significant.

Until more published data is known about this drug in relation to breastfeeding, alternatives with a known safer pharmacokinetic profile for breastfeeding may be preferable, especially during the neonatal period and in the event of prematurity.

Expert authors consider the use of gold salts during lactation to be low risk (Ostensen 1992, Needs 1985). Other authors believe that they best be avoided during breastfeeding (Janssen 2000, Byron 1987, Ostensen 1986).
American Academy of Pediatrics: Gold salts are medications usually compatible with breastfeeding (AAP 2001).


See below the information of this related product:

  • Aurothiomalate Sodium (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Auranofin in other languages or writings:

Tradenames

Main tradenames from several countries containing Auranofin in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 25 %
Molecular weight 679 daltons
Protein Binding 60 %
Tmax 1.5 -2.5 hours
408 - 1939 hours

References

  1. Xediton. Auranofin (Ridaura). Drug Summary. 2010 Full text (in our servers)
  2. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med. 2000 Abstract Full text (link to original source) Full text (in our servers)
  3. Ostensen M. Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation. Am J Reprod Immunol. 1992 Abstract
  4. Ostensen M, Skavdal K, Myklebust G, Tomassen Y, Aarbakke J. Excretion of gold into human breast milk. Eur J Clin Pharmacol. 1986;31(2):251-2. Abstract
  5. Needs CJ, Brooks PM. Antirheumatic medication during lactation. Br J Rheumatol. 1985 Abstract

Total visits

3,757

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM